Method of treating cytomegalovirus with DC-SIGN blockers

Details Method of treating cytomegalovirus with DC-SIGN blockers Method of treating cytomegalovirus with DC-SIGN blockers

2003-11-05

2008-09-23

Chen, Stacy B (Department: 1648)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving virus or bacteriophage

C435S007100, C424S230100

Reexamination Certificate

active

07427469

ABSTRACT:
The present invention relates to methods and compositions for preventing or treating diseases of a mammal, including viral infections, wherein at least one symptom of the disease is mediated at least in part by the binding of an effector molecule to a DC-SIGN receptor present on cells of the mammal to be treated. The invention also provides methods of identifying compositions, wherein the compositions are useful for treating mammalian diseases, including viral infections, for which at least one symptom of the disease is mediated at least in part by the specific binding of an effector molecule to a DC-SIGN receptor present on the cells that express the DC-SIGN receptor, belonging to the mammal to be treated. The invention further relates to compositions and methods for targeting subject molecules to cells that express the DC-SIGN receptor.

REFERENCES:
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5498538 (1996-03-01), Kay et al.
patent: 5516637 (1996-05-01), Huang et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5567582 (1996-10-01), Grundy et al.
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5625033 (1997-04-01), Kay et al.
patent: 5658727 (1997-08-01), Barbas et al.
patent: 5667988 (1997-09-01), Barbas et al.
patent: 6391567 (2002-05-01), Littman et al.
patent: 2004/0197330 (2004-10-01), Amara et al.
patent: EP 1046651 (2000-10-01), None
patent: WO 91/05876 (1991-05-01), None
patent: WO 93/01820 (1993-02-01), None
patent: WO 00/63251 (2000-10-01), None
patent: WO 01/64752 (2001-09-01), None
patent: WO 02/080851 (2002-10-01), None
Desrosiers, R. Prospects for an AIDS vaccine, Nature Medicine, 2004, 10(3):221-223.
Feinberg et al. AIDS vaccine models: challenging challenge viruses, Nature Medicine, 2002, 8(3):207-210.
Greene, W. The brightening future of HIV therapeutics, Nature Immunology, 2004, 5(9):867-871.
Wang et al. Recombinant Modified Vaccinia Virus Ankara Expressing a Soluble Form of Glycoprotein B, 2004, 78(8):3965-3976.
MacDonald et al. Mucosal and Parenteral Vaccination against Acute and Latent MCMV, J. Virology, 1998, 72(1):442-451.
Centers for Disease Control, National Center for Infectious Diseases Cytomegalovirus Infection, website last updated 2002 http://www.cdc.gov
cidod/diseases/cmv.htm.
Pass et al., The Journal of Infectious Diseases, 1999, 180:970-975.
Cunningham et al. The New England Journal of Medicine, 1998, 339(4):236-244.
Geijtenbeek et al. Cell, 2000, 100:587-597.
Kwon et al.; “DC-Sign-Mediated Internalization of HIV is Required forTrans-Enhancement of T Cell Infection”;Immunity, vol. 16, No. 1, pp. 135-144, (2002).
Navarro-Sanchez et al.; “Dendritic-Cell-Specific ICAM3-Grabbing Non-Integrin is Essential for the Productive Infection of Human Dendritic Cells by Mosquito-Cell-Derived Dengue Viruses”; EMBO Reports, vol. 4, No. 7, pp. 723-728, (2003).
Tassaneetrithep et al.; “DC-SING (CD209) Mediates Dengue Virus Infection of Human Dendritic Cells”; Journal of Experimental Medicine, vol. 197, No. 7, pp. 823-829, (2003).
Men et al. Identification of Chimpanzee fab Fragments, Journal of Virology, 2004, 78(9): 4665-4674.
Brandriss et al. “Lethal 17D Yellow Fever Encephalitis in Mice”, Journal of General Virology, 1986, 67:229-234.
Lyssen et al., Perspectives for the Treatment of Infections with Flavivirdae, Clinical Microbiology Reviews, 2000, 13(1):67-82.
U.S. Appl. No. 10/464,531 of Oliver Neyrolles, Oliver Schwartz, Ludvic Tailleux, and Philippe Lagrange, filed Jun. 19, 2003.
U.S. Appl. No. 10/533,924 of Ali Amara et al., filed May 4, 2005, as a 371 of PCT/IB2003/005569, filed Nov. 5, 2003.
Office Action dated Dec. 28, 2004, in U.S. Appl. No. 10/700,491.
Office Action dated Jul. 26, 2005, in U.S. Appl. No. 10/700,491.
Office Action mailed Jun. 7, 2006, in U.S. Appl. No. 10/700,491, which was filed Nov. 5, 2003.
Curtis, Benson M. et al., “Sequence and Expression of a Membrane-Associated C-type Lectin that Exhibits CD4-Independent Binding of Human Immunodeficiency Virus Envelope Glycoprotein gp120,”Proc. Natl. Acad. Sci. USA, vol. 89, pp. 8356-8360 (1992).
Geijtenbeek, Teunis B.H. et al., “Identification of DC-Sign, a Novel Dendritic Cell-Specific ICAM-3 Receptor that Supports Primary Immune Responses,”Cell, vol. 100, pp. 575-585 (2000).
Halary, Franck et al., “Human Cytomegalovirus Binding to DC-Sign is Required for Dendritic Cell Infection and Target Celltrans-Infection,”Immunuty, vol. 17, pp. 653-664 (2002).
Tailleux, Ludovic et al., “DC-Sign is the Major Mycobacterium Tuberculosis Receptor on Human Dendritic Cells,”The Journal of Experimental Medicine, vol. 197, pp. 121-127 (2003).
U.S. Appl. No. 10/464,531 of Olivier Neyrolles, Olivier Schwartz, Ludovic Tailleux, and Philippe Lagrange, filed Jun. 19, 2003.
U.S. Appl. No. 10/700,507 of Ali Amara, Frank Halary, Julie Dechanet-Merville, Jean-Francois Moreau, Fernando Arenzana-Seisdedos and Thierry Delaunay, filed Nov. 5, 2003.

Affiliated with

Also associated with

Rating

Method of treating cytomegalovirus with DC-SIGN blockers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treating cytomegalovirus with DC-SIGN blockers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating cytomegalovirus with DC-SIGN blockers will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3987846